Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR3A1 Inhibitors

OR3A1 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of OR3A1, a member of the olfactory receptor (OR) family of G-protein-coupled receptors (GPCRs). Olfactory receptors such as OR3A1 play a crucial role in detecting odorant molecules in the nasal epithelium, initiating a signal transduction pathway that leads to the perception of smell. When an odorant binds to OR3A1, it activates a G-protein, which in turn triggers a cascade of intracellular events, leading to changes in cellular signaling and the transmission of signals to the olfactory bulb in the brain. Beyond its role in olfaction, OR3A1, like many other olfactory receptors, is believed to be expressed in other tissues, where it might participate in various physiological processes not directly related to sensory perception.

The study of OR3A1 inhibitors helps researchers understand the specific functions of OR3A1 within both olfactory and non-olfactory contexts. By inhibiting OR3A1, scientists can explore the effects on signal transduction pathways linked to olfaction, providing insight into the molecular mechanisms underlying odor detection and interpretation. Additionally, given the potential presence of OR3A1 in non-olfactory tissues, these inhibitors serve as valuable tools for investigating the broader roles of OR3A1 in cellular communication and metabolism. Inhibiting OR3A1 allows researchers to dissect the complex interactions between olfactory receptors and other cellular signaling pathways, leading to a more comprehensive understanding of how GPCRs like OR3A1 regulate diverse biological processes. This contributes to the broader study of olfactory receptors as multifunctional proteins that may play important roles beyond their traditional function in the sense of smell.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Suramin sodium

129-46-4sc-507209
sc-507209F
sc-507209A
sc-507209B
sc-507209C
sc-507209D
sc-507209E
50 mg
100 mg
250 mg
1 g
10 g
25 g
50 g
$152.00
$214.00
$728.00
$2601.00
$10965.00
$21838.00
$41096.00
5
(1)

Allosteric inhibitor that can modify GPCR conformation and inhibit receptor signaling.

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

β-adrenergic receptor antagonist that can alter GPCR-mediated signaling pathways.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$51.00
$171.00
$530.00
2
(1)

Selective antagonist of α2-adrenergic receptors that can inhibit related GPCR function.

Losartan

114798-26-4sc-353662
100 mg
$130.00
18
(1)

Angiotensin II receptor antagonist that can modulate GPCR activity related to angiotensin signaling.

Clozapine

5786-21-0sc-200402
sc-200402A
sc-200402B
sc-200402C
50 mg
500 mg
5 g
10 g
$69.00
$364.00
$2500.00
$4100.00
11
(1)

Dopamine antagonist that can inhibit GPCR-related dopamine signaling pathways.

Ondansetron

99614-02-5sc-201127
sc-201127A
10 mg
50 mg
$82.00
$333.00
1
(0)

Selective 5-HT3 receptor antagonist that can inhibit serotonin signaling through GPCRs.

Naloxone

465-65-6sc-477809
200 mg
$306.00
5
(0)

Opioid receptor antagonist that can block opioid signaling through GPCRs.

SCH 23390

125941-87-9sc-200408
sc-200408A
5 mg
25 mg
$179.00
$733.00
2
(1)

Dopamine D1 receptor antagonist that can alter signaling pathways involving related GPCRs.